~~<i id='5B386F21D4'><strike id='5B386F21D4'><tt id='5B386F21D4'><pre id='5B386F21D4'></pre></tt></strike></i>~~

Home» explore» fashion

fashion

author：comprehensive 2025-09-29 06:10:38 Page View：838

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Princess Kate attends Wimbledon with Roger Federer: See the photos
Next article： Jerome Adams on the need for new antivirals for Covid

comprehensive

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

Biden's Plan B on student loan forgiveness relies on Higher Education Act: What to know

2:59PresidentJoeBidenspeaksabouthisplansforcontinuedstudentdebtreliefafteraU.S.SupremeCourtdecisionb

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

Myanmar's Supreme Court hears arguments in 2 appeals by ousted leader Aung San Suu Kyi

FILE-Myanmar'sleaderAungSanSuuKyi,left,attendsthebilateralmeetingwithChinesePresidentXiJinpingatthep